#United States #Boston #Privo Technologies #PRV111 #Oral Cancer

Clinical Breakthrough for Oral Cancer Treatment

In a groundbreaking update, Privo Technologies has announced significant results from its ongoing Phase 2 clinical trial of PRV111, a novel therapy designed for early-stage oral cancers. With a remarkable 95.5% pathologic complete response (pCR) rate, the treatment has shown extraordinary potential to revolutionize the management of conditions such as non-invasive oral cancer and high-grade dysplasia (HGD).

Trial Overview

Conducted at four prominent hospitals across the United States known for their expertise in head and neck cancers, the CLN-004 Phase 2 trial evaluated 22 patients undergoing treatment with PRV111. Impressively, 21 out of 22 patients achieved marked responses, characterized as a complete absence of dysplastic cells in follow-up biopsies. The remaining participant saw their condition improved enough to downgrade from oral carcinoma in situ to a less severe form known as low-grade dysplasia.

What sets this treatment apart is its ability to eliminate the need for surgical excision. Unlike conventional approaches which often require repetitive surgeries causing anatomical distortion and functional impairments, PRV111 enables full recovery of the treated mucosa without any visible scarring. Patients in the study reported that their mucosal surfaces returned to normal after treatment, a promising development for preserving quality of life, including speech and swallowing capabilities.

Durability and Tolerance

Even after a median follow-up of approximately 14 months, no recurrence of the disease has been noted in any participant. This sustained benefit is particularly encouraging given the chronic nature of the conditions being treated. Dr. Eric Lamarre, who served as the lead investigator for this trial and is the Chief of Head and Neck Surgical Oncology at Cleveland Clinic, noted that “the complete response rate of 95.5%, along with the durability of treatment outcomes achieved with PRV111, is among the highest reported for localized therapies in this area.” He emphasized PRV111’s ability to offer a non-surgical alternative to patients, especially vital for those facing the repetitive burden of surgical procedures.

Furthermore, the treatment has demonstrated excellent tolerance among participants. Treatment-related adverse effects were mostly mild and transient, with 85% of side effects being categorized as minor. Notably, no severe systemic toxicities were reported, keeping the health risks associated with treatment to a minimum.

Transforming Treatment

The results gathered from the CLN-004 study build on prior clinical experiences from Privo's earlier trial, CLN-001, which indicated promising localized tumor responses. While traditional surgeries often lead to high recurrence rates and are associated with significant morbidity, PRV111 offers a novel delivery method of cisplatin, a chemotherapy drug, directly to affected tissues through a nanoengineered patch. This approach minimizes systemic exposure and significantly reduces overall treatment burden on patients.

Dr. Manijeh Goldberg, PhD, MBA, the CEO of Privo Technologies, expressed her excitement about the trial’s findings, stating, “We are one step closer to providing patients with a non-surgical alternative to repeated operative procedures.”

Conclusion

As PRV111 continues to show efficacy in treating early-stage oral cancers, its introduction could reshape the standard of care in this field. With its promising outcomes, Privo Technologies is diligently working towards further advancing this therapy, ultimately underscoring their commitment to improving patient outcomes and enhancing the quality of life for individuals dealing with cancer. With ongoing monitoring and research, PRV111 could soon herald a new paradigm in oncology treatment, culminating in less invasive, more enduring options for patients worldwide.

For more updates on PRV111 and other innovations from Privo Technologies, visit Privo Technologies.